Hui Zhao

Anhui Medical University - Department of Respiratory and Critical Care Medicine

Hefei

China

SCHOLARLY PAPERS

3

DOWNLOADS

78

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (828,027)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

2.

Central Nervous System Efficacy of Rezivertinib (BPI-7711) in Advanced NCLC Patients with EGFR T790m Mutation: A Pooled Analysis of Two Clinical Trials

Number of pages: 33 Posted: 20 Mar 2023
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - First Hospital, Shanxi Medical University - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Harbin Medical University - Department of Medical Oncology, Army Medical University - Institute of Cancer, Zhengzhou University - Department of Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Peking University - Department of Thoracic Medical Oncology, Qingdao University - Yantai Yuhuangding Hospital, Zhejiang University - The First Affiliated Hospital, Central South University - Thoracic Medicine Department II, Bengbu Medical College - First Affiliated Hospital, Sichuan University - Department of Thoracic Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Shandong First Medical University - Department of Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Chongqing University Cancer Hospital, Soochow University - Department of Pulmonary and Critical Care Medicine, Xingtai Medical College - Cancer Center, Nanjing Medical University - Department of Oncology, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Huazhong University of Science and Technology - Tongji Medical College, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Xuzhou Medical University - Department of Radiotherapy, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Anhui Medical University - Department of Oncology, Soochow University - Second Affiliated Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 20 (1,070,076)

Abstract:

Loading...

Rezivertinib, BPI-7711, EGFR T790M mutation, CNS, NSCLC

3.

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent EGFR T790M Mutated NSCLC: A Phase IIb Study

Number of pages: 254 Posted: 11 May 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - Department of Medical Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Central South University - Thoracic Medicine Department II, Sichuan University - Department of Thoracic Oncology, Zhengzhou University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Army Medical University - Institute of Cancer, Harbin Medical University - Department of Respiratory Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Shandong First Medical University - Department of Oncology, Peking University - Department of Thoracic Medical Oncology, Xingtai Medical College - Cancer Center, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Zhengzhou University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Chongqing University Cancer Hospital - Department of Palliative Care, Xuzhou Medical University - Department of Radiotherapy, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Nanjing Medical University - Department of Oncology, Anhui Medical University - Department of Oncology, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 13 (1,157,102)

Abstract:

Loading...

Rezivertinib, BPI-7711, NSCLC, EGFR T790M mutation, Third-generation EGFR TKI